Please use this identifier to cite or link to this item:
標題: CCN2 Enhances Resistance to Cisplatin-Mediating Cell Apoptosis in Human Osteosarcoma
作者: Tsai, Hsiao-Chi
Huang, Chun-Yin
Su, Hong-Lin
Tang, Chih-Hsin
關鍵字: Animals;Antineoplastic Agents;Apoptosis;Bone Neoplasms;Cell Death;Cell Line, Tumor;Cisplatin;Connective Tissue Growth Factor;Disease Models, Animal;Drug Resistance, Neoplasm;Focal Adhesion Protein-Tyrosine Kinases;Gene Expression Regulation, Neoplastic;Humans;Inhibitor of Apoptosis Proteins;MAP Kinase Signaling System;Osteosarcoma;Tumor Burden;Xenograft Model Antitumor Assays;bcl-X Protein
Project: PLoS ONE, Volume 9, Issue 3, Page(s) e90159.
Osteosarcoma (OS) is the most common form of malignant bone tumor and is an aggressive malignant neoplasm exhibiting osteoblastic differentiation. Cisplatin is one of the most efficacious antitumor drugs for osteosarcoma patients. However, treatment failures are common due to the development of chemoresistance. CCN2 (also known as CTGF), is a secreted protein that binds to integrins, modulates the invasive behavior of certain human cancer cells. However, the effect of CCN2 in cisplatin-mediated chemotherapy is still unknown. Here, we found that CCN2 was upregulated in human osteosarcoma cells after treatment with cisplatin. Moreover, overexpression of CCN2 increased the resistance to cisplatin-mediated cell apoptosis. In contrast, reduction of CCN2 by CCN2 shRNA promoted the chemotherapeutic effect of cisplatin. We also found that CCN2 provided resistance to cisplatin-induced apoptosis through upregulation of Bcl-xL and survivin. Knockdown of Bcl-xL or survivin removed the CCN2-mediated resistance to apoptosis induced by cisplatin. On the other hand, CCN2 also promoted FAK, MEK, and ERK survival signaling pathways to enhance tumor survival during cisplatin treatment. In a mouse xenograft model, overexpression of CCN2 promoted resistance to cisplatin. However, knockdown of CCN2 increased the therapeutic effect of cisplatin. Therefore, our data suggest that CCN2 might be a critical oncogene of human osteosarcoma for cisplatin-resistance and supported osteosarcoma cell growth in vivo and in vitro.
ISSN: 1932-6203
DOI: 10.1371/journal.pone.0090159
Appears in Collections:生命科學系所

Files in This Item:
File Description SizeFormat Existing users please Login
2015-3-6-1-7-5.pdf1.26 MBAdobe PDFThis file is only available in the university internal network   
Show full item record

Google ScholarTM




Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.